Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.70 |
| ▸ | DRD2 | P14416 | 4/20 | 0.66 |
| ▸ | HTR2A | P28223 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2549342 | 0.98 | SIGMAR1 (0.72) | SIGMAR1DRD2HTR2AKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL7982019 | 0.97 | SIGMAR1 (0.70) | SIGMAR1DRD2HTR2AKMT2AMEN1 | |
| SCHEMBL7972984 | 0.94 | DRD2 (0.69) | SIGMAR1DRD2HTR2AKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL7983779 | 0.93 | DRD2 (0.68) | SIGMAR1DRD2HTR2AKMT2AMEN1 | |
| SCHEMBL10153569 | 0.88 | KMT2A (0.69) | SIGMAR1DRD2HTR2AKMT2AMEN1 | |
| SCHEMBL18770805 | 0.88 | DRD2 (0.82) | SIGMAR1DRD2HTR2AKMT2AMEN1 | |
| SCHEMBL10724043 | 0.85 | SIGMAR1 (0.70) | SIGMAR1DRD2HTR2AKMT2AMEN1 | |
| SCHEMBL10723980 | 0.85 | SIGMAR1 (0.70) | SIGMAR1DRD2HTR2AKMT2AMEN1 | |
| SCHEMBL10722011 | 0.85 | SIGMAR1 (0.70) | SIGMAR1DRD2HTR2AKMT2AMEN1 | |
| SCHEMBL30671731 | 0.84 | SIGMAR1 (0.97) | SIGMAR1DRD2HTR2AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067607-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | WANG, ZHEMING (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240067607-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | WANG, ZHEMING (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240067607-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | WANG, ZHEMING (CN) | 2024-02-29 | — | — | US | disclosed |
| US-11873284-B2 | Pyridinylcyanoguanidine derivative and use thereof | WANG, Zheming (CN) | 2024-01-16 | — | — | US | disclosed |
| US-11873284-B2 | Pyridinylcyanoguanidine derivative and use thereof | WANG, Zheming (CN) | 2024-01-16 | — | — | US | disclosed |
| US-11873284-B2 | Pyridinylcyanoguanidine derivative and use thereof | WANG, Zheming (CN) | 2024-01-16 | — | — | US | disclosed |
| CN-116332917-A | Pyridine cyanoguanidine derivative and application thereof | 王喆明 | 2023-06-27 | — | — | CN | disclosed |
| US-20230192615-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | Rushi Biotech (Hangzhou) Co., Ltd (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192615-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | Rushi Biotech (Hangzhou) Co., Ltd (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192615-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | Rushi Biotech (Hangzhou) Co., Ltd (CN) | 2023-06-22 | — | — | US | disclosed |
| WO-2011121055-A1 | PYRIDINYL DERIVATIVES COMPRISING A CYANOGUANIDINE OR SQUARIC ACID MOIETY | TOPOTARGET A/S (DK) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011121055-A1 | PYRIDINYL DERIVATIVES COMPRISING A CYANOGUANIDINE OR SQUARIC ACID MOIETY | TOPOTARGET A/S (DK) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067607-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | NAMPT, NAPRT, NNMT | SIGMAR1 3861/4885DRD2 1634/4885HTR2A 1216/4885 |
| US-11873284-B2 | Pyridinylcyanoguanidine derivative and use thereof | NAMPT, NAPRT, NNT | SIGMAR1 3950/4885DRD2 1688/4885HTR2A 1275/4885 |
| US-20230192615-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | NAMPT, NAPRT, NNT | SIGMAR1 3950/4885DRD2 1688/4885HTR2A 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.